Search

Your search keyword '"Seferovic, Petar M"' showing total 370 results
Start Over Author "Seferovic, Petar M"
370 results on '"Seferovic, Petar M"'

1. Natriuretic Peptides: Role in the Diagnosis and Management of Heart Failure: A Scientific Statement From the Heart Failure Association of the European Society of Cardiology, Heart Failure Society of America and Japanese Heart Failure Society

Author

Tsutsui, HIROYUKI, ALBERT, NANCY M., COATS, ANDREW J.S., ANKER, STEFAN D., BAYES-GENIS, ANTONI, BUTLER, JAVED, CHIONCEL, OVIDIU, DEFILIPPI, CHRISTOPHER R., DRAZNER, MARK H., FELKER, G. MICHAEL, FILIPPATOS, GERASIMOS, FIUZAT, MONA, IDE, TOMOMI, JANUZZI, JAMES L., Jr, KINUGAWA, KOICHIRO, KUWAHARA, KOICHIRO, MATSUE, YUYA, MENTZ, ROBERT J., METRA, MARCO, PANDEY, AMBARISH, ROSANO, GIUSEPPE, SAITO, YOSHIHIKO, SAKATA, YASUSHI, SATO, NAOKI, SEFEROVIC, PETAR M., TEERLINK, JOHN, YAMAMOTO, KAZUHIRO, and YOSHIMURA, MICHIHIRO

Published
2023
Full Text
View/download PDF

2. How to tackle therapeutic inertia in heart failure with reduced ejection fraction. A scientific statement of the Heart Failure Association of the ESC

Author

Savarese, Gianluigi, primary, Lindberg, Felix, additional, Cannata, Antonio, additional, Chioncel, Ovidiu, additional, Stolfo, Davide, additional, Musella, Francesca, additional, Tomasoni, Daniela, additional, Abdelhamid, Magdy, additional, Banerjee, Debasish, additional, Bayes‐Genis, Antoni, additional, Berthelot, Emmanuelle, additional, Braunschweig, Frieder, additional, Coats, Andrew J.S., additional, Girerd, Nicolas, additional, Jankowska, Ewa A., additional, Hill, Loreena, additional, Lainscak, Mitja, additional, Lopatin, Yury, additional, Lund, Lars H., additional, Maggioni, Aldo P., additional, Moura, Brenda, additional, Rakisheva, Amina, additional, Ray, Robin, additional, Seferovic, Petar M., additional, Skouri, Hadi, additional, Vitale, Cristiana, additional, Volterrani, Maurizio, additional, Metra, Marco, additional, and Rosano, Giuseppe M.C., additional

Published
2024
Full Text
View/download PDF

4. Endomyocardial biopsy: safety and prognostic utility in paediatric and adult myocarditis in the European Society of Cardiology EURObservational Research Programme Cardiomyopathy and Myocarditis Long-Term Registry.

Author

Caforio, Alida L P, Kaski, Juan P, Gimeno, Juan R, Elliott, Perry M, Laroche, Cecile, Tavazzi, Luigi, Tendera, Michal, Fu, Michael, Sala, Simone, Seferovic, Petar M, Heliö, Tiina, Calò, Leonardo, Blagova, Olga, Amin, Ahmad, Kindermann, Ingrid, Sinagra, Gianfranco, Frustaci, Andrea, Bonnet, Daniel, Charron, Philippe, and Maggioni, Aldo P

Subjects
VENTRICULAR ejection fraction, IMPLANTABLE cardioverter-defibrillators, CARDIAC magnetic resonance imaging, MYOCARDITIS, CARDIAC research, HEART assist devices, CHILD patients
Abstract

Background and Aims Contemporary multicentre data on clinical and diagnostic spectrum and outcome in myocarditis are limited. Study aims were to describe baseline features, 1-year follow-up, and baseline predictors of outcome in clinically suspected or biopsy-proven myocarditis (2013 European Society of Cardiology criteria) in adult and paediatric patients from the EURObservational Research Programme Cardiomyopathy and Myocarditis Long-Term Registry. Methods Five hundred eighty-one (68.0% male) patients, 493 adults, median age 38 (27–52) years, and 88 children, aged 8 (3–13) years, were divided into 3 groups: Group 1 (n = 233), clinically suspected myocarditis with abnormal cardiac magnetic resonance; Group 2 (n = 222), biopsy-proven myocarditis; and Group 3 (n = 126) clinically suspected myocarditis with normal or inconclusive or no cardiac magnetic resonance. Baseline features were analysed overall, in adults vs. children, and among groups. One-year outcome events included death/heart transplantation, ventricular assist device (VAD) or implantable cardioverter defibrillator (ICD) implantation, and hospitalization for cardiac causes. Results Endomyocardial biopsy, mainly right ventricular, had a similarly low complication rate in children and adults (4.7% vs. 4.9%, P = NS), with no procedure-related death. A classical myocarditis pattern on cardiac magnetic resonance was found in 31.3% of children and in 57.9% of adults with biopsy-proven myocarditis (P <.001). At 1-year follow-up, 11/410 patients (2.7%) died, 7 (1.7%) received a heart transplant, 3 underwent VAD (0.7%), and 16 (3.9%) underwent ICD implantation. Independent predictors at diagnosis of death or heart transplantation or hospitalization or VAD implantation or ICD implantation at 1-year follow-up were lower left ventricular ejection fraction and the need for immunosuppressants for new myocarditis diagnosis refractory to non–aetiology-driven therapy. Conclusions Endomyocardial biopsy was safe, and cardiac magnetic resonance using Lake Louise criteria was less sensitive, particularly in children. Virus-negative lymphocytic myocarditis was predominant both in children and adults, and use of immunosuppressive treatments was low. Lower left ventricular ejection fraction and the need for immunosuppressants at diagnosis were independent predictors of unfavourable outcome events at 1 year. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

5. Heart Failure Association, Heart Failure Society of America, and Japanese Heart Failure Society Position Statement on Endomyocardial Biopsy

Author

Seferović, Petar M., Tsutsui, Hiroyuki, Mcnamara, Dennis M., Ristić, Arsen D., Basso, Cristina, Bozkurt, Biykem, Cooper, Leslie T., Filippatos, Gerasimos, Ide, Tomomi, Inomata, Takayuki, Klingel, Karin, Linhart, Aleš, lyon, Alexander R., Mehra, Mandeep R., Polovina, Marija, Milinković, Ivan, Nakamura, Kazufumi, Anker, Stefan D., Veljić, Ivana, Ohtani, Tomohito, Okumura, Takahiro, Thum, Thomas, Tschöpe, Carsten, Rosano, Giuseppe, Coats, Andrew J.S., and Starling, Randall C.

Published
2021
Full Text
View/download PDF

7. Cardiopoietic cell therapy for advanced ischemic heart failure: results at 39 weeks of the prospective, randomized, double blind, sham-controlled CHART-1 clinical trial

Author

Bartunek, Jozef, Terzic, Andre, Davison, Beth A, Filippatos, Gerasimos S, Radovanovic, Slavica, Beleslin, Branko, Merkely, Bela, Musialek, Piotr, Wojakowski, Wojciech, Andreka, Peter, Horvath, Ivan G, Katz, Amos, Dolatabadi, Dariouch, El Nakadi, Badih, Arandjelovic, Aleksandra, Edes, Istvan, Seferovic, Petar M, Obradovic, Slobodan, Vanderheyden, Marc, Jagic, Nikola, Petrov, Ivo, Atar, Shaul, Halabi, Majdi, Gelev, Valeri L, Shochat, Michael K, Kasprzak, Jaroslaw D, Sanz-Ruiz, Ricardo, Heyndrickx, Guy R, Nyolczas, Noémi, Legrand, Victor, Guédès, Antoine, Heyse, Alex, Moccetti, Tiziano, Fernandez-Aviles, Francisco, Jimenez-Quevedo, Pilar, Bayes-Genis, Antoni, Hernandez-Garcia, Jose Maria, Ribichini, Flavio, Gruchala, Marcin, Waldman, Scott A, Teerlink, John R, Gersh, Bernard J, Povsic, Thomas J, Henry, Timothy D, Metra, Marco, Hajjar, Roger J, Tendera, Michal, Behfar, Atta, Alexandre, Bertrand, Seron, Aymeric, Stough, Wendy Gattis, Sherman, Warren, Cotter, Gad, and Wijns, William

Subjects
Heart Disease, Clinical Research, Clinical Trials and Supportive Activities, Cardiovascular, Stem Cell Research, Adult, Aged, Double-Blind Method, Female, Heart Failure, Humans, Male, Mesenchymal Stem Cell Transplantation, Middle Aged, Myocardial Ischemia, Prospective Studies, Treatment Outcome, Young Adult, Regenerative medicine, Cardiopoiesis, Cardiovascular disease, Stem cell, Target population, Disease severity, Marker, Precision medicine, CHART Program, Cardiorespiratory Medicine and Haematology, Clinical Sciences, Cardiovascular System & Hematology
Abstract

AimsCardiopoietic cells, produced through cardiogenic conditioning of patients' mesenchymal stem cells, have shown preliminary efficacy. The Congestive Heart Failure Cardiopoietic Regenerative Therapy (CHART-1) trial aimed to validate cardiopoiesis-based biotherapy in a larger heart failure cohort.Methods and resultsThis multinational, randomized, double-blind, sham-controlled study was conducted in 39 hospitals. Patients with symptomatic ischaemic heart failure on guideline-directed therapy (n = 484) were screened; n = 348 underwent bone marrow harvest and mesenchymal stem cell expansion. Those achieving > 24 million mesenchymal stem cells (n = 315) were randomized to cardiopoietic cells delivered endomyocardially with a retention-enhanced catheter (n = 157) or sham procedure (n = 158). Procedures were performed as randomized in 271 patients (n = 120 cardiopoietic cells, n = 151 sham). The primary efficacy endpoint was a Finkelstein-Schoenfeld hierarchical composite (all-cause mortality, worsening heart failure, Minnesota Living with Heart Failure Questionnaire score, 6-min walk distance, left ventricular end-systolic volume, and ejection fraction) at 39 weeks. The primary outcome was neutral (Mann-Whitney estimator 0.54, 95% confidence interval [CI] 0.47-0.61 [value > 0.5 favours cell treatment], P = 0.27). Exploratory analyses suggested a benefit of cell treatment on the primary composite in patients with baseline left ventricular end-diastolic volume 200-370 mL (60% of patients) (Mann-Whitney estimator 0.61, 95% CI 0.52-0.70, P = 0.015). No difference was observed in serious adverse events. One (0.9%) cardiopoietic cell patient and 9 (5.4%) sham patients experienced aborted or sudden cardiac death.ConclusionThe primary endpoint was neutral, with safety demonstrated across the cohort. Further evaluation of cardiopoietic cell therapy in patients with elevated end-diastolic volume is warranted.

Published
2017

8. Prevention and rehabilitation after heart transplantation: A clinical consensus statement of the European Association of Preventive Cardiology, Heart Failure Association of the ESC, and the European Cardio Thoracic Transplant Association, a section of ESOT

Author

Simonenko, Maria, Hansen, Dominique, Niebauer, Josef, Volterrani, Maurizio, Adamopoulos, Stamatis, Amarelli, Cristiano, Ambrosetti, Marco, Anker, Stefan D, Bayes-Genis, Antonio, Gal, Tuvia Ben, Bowen, T Scott, Cacciatore, Francesco, Caminiti, Giuseppe, Cavarretta, Elena, Chioncel, Ovidiu, Coats, Andrew J S, Cohen-Solal, Alain, D’Ascenzi, Flavio, de Pablo Zarzosa, Carmen, Gevaert, Andreas B, Gustafsson, Finn, Kemps, Hareld, Hill, Loreena, Jaarsma, Tiny, Jankowska, Ewa, Joyce, Emer, Krankel, Nicolle, Lainscak, Mitja, Lund, Lars H, Moura, Brenda, Nytrøen, Kari, Osto, Elena, Piepoli, Massimo, Potena, Luciano, Rakisheva, Amina, Rosano, Giuseppe, Savarese, Gianluigi, Seferovic, Petar M, Thompson, David R, Thum, Thomas, and Van Craenenbroeck, Emeline M

Abstract

Little is known either about either physical activity patterns, or other lifestyle-related prevention measures in heart transplantation (HTx) recipients. The history of HTx started more than 50 years ago but there are still no guidelines or position papers highlighting the features of prevention and rehabilitation after HTx. The aims of this scientific statement are (i) to explain the importance of prevention and rehabilitation after HTx, and (ii) to promote the factors (modifiable/non-modifiable) that should be addressed after HTx to improve patients’ physical capacity, quality of life and survival. All HTx team members have their role to play in the care of these patients and multidisciplinary prevention and rehabilitation programmes designed for transplant recipients. HTx recipients are clearly not healthy disease-free subjects yet they also significantly differ from heart failure patients or those who are supported with mechanical circulatory support. Therefore, prevention and rehabilitation after HTx both need to be specifically tailored to this patient population and be multidisciplinary in nature. Prevention and rehabilitation programmes should be initiated early after HTx and continued during the entire post-transplant journey. This clinical consensus

Published
2024
Full Text
View/download PDF

9. Sacubitril/valsartan for the treatment of non‐obstructive hypertrophic cardiomyopathy: An open label randomized controlled trial (SILICOFCM).

Author

Velicki, Lazar, Popovic, Dejana, Okwose, Nduka C., Preveden, Andrej, Tesic, Milorad, Tafelmeier, Maria, Charman, Sarah J., Barlocco, Fausto, MacGowan, Guy A., Seferovic, Petar M., Filipovic, Nenad, Ristic, Arsen, Olivotto, Iacopo, Maier, Lars S., Jakovljevic, Djordje G., Redzek, Aleksandar, Bjelobrk, Marija, Ilic, Aleksandra, Golubovic, Miodrag, and Miljkovic, Tatjana

Subjects
HYPERTROPHIC cardiomyopathy, ENTRESTO, VALSARTAN, EXERCISE physiology, NATRIURETIC peptides, VENTRICULAR ejection fraction
Abstract

Aim: Sacubitril/valsartan treatment reduces mortality and hospitalizations in heart failure with reduced ejection fraction but has limited application in hypertrophic cardiomyopathy (HCM). The aim of this study was to evaluate the effect of sacubitril/valsartan on peak oxygen consumption (VO2) in patients with non‐obstructive HCM. Methods and results: This is a phase II, randomized, open‐label multicentre study that enrolled adult patients with symptomatic non‐obstructive HCM (New York Heart Association class I–III) who were randomly assigned (2:1) to receive sacubitril/valsartan (target dose 97/103 mg) or control for 16 weeks. The primary endpoint was a change in peak VO2. Secondary endpoints included echocardiographic measures of cardiac structure and function, natriuretic peptides and other cardiac biomarkers, and Minnesota Living with Heart Failure quality of life. Between May 2018 and October 2021, 354 patients were screened for eligibility, 115 patients (mean age 58 years, 37% female) met the study inclusion criteria and were randomly assigned to sacubitril/valsartan (n = 79) or control (n = 36). At 16 weeks, there was no significant change in peak VO2 from baseline in the sacubitril/valsartan (15.3 [4.3] vs. 15.9 [4.3] ml/kg/min, p = 0.13) or control group (p = 0.47). No clinically significant changes were found in blood pressure, cardiac structure and function, plasma biomarkers, or quality of life. Conclusion: In patients with HCM, a 16‐week treatment with sacubitril/valsartan was well tolerated but had no effect on exercise capacity, cardiac structure, or function. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

11. Cardio‐renal‐metabolic disease in primary care setting.

Author

Ibrahim, Mahmoud, Ba‐Essa, Ebtesam M., Baker, Jason, Cahn, Avivit, Ceriello, Antonio, Cosentino, Francesco, Davies, Melanie J., Eckel, Robert H., Van Gaal, Luc, Gaede, Peter, Handelsman, Yehuda, Klein, Samuel, Leslie, Richard David, Pozzilli, Paolo, Del Prato, Stefano, Prattichizzo, Francesco, Schnell, Oliver, Seferovic, Petar M., Standl, Eberhard, and Thomas, Abraham

Subjects
CONTINUOUS glucose monitoring, PRIMARY care, TYPE 2 diabetes, HYPOGLYCEMIA, HEART diseases
Abstract

In the primary care setting providers have more tools available than ever before to impact positively obesity, diabetes, and their complications, such as renal and cardiac diseases. It is important to recognise what is available for treatment taking into account diabetes heterogeneity. For those who develop type 2 diabetes (T2DM), effective treatments are available that for the first time have shown a benefit in reducing mortality and macrovascular complications, in addition to the well‐established benefits of glucose control in reducing microvascular complications. Some of the newer medications for treating hyperglycaemia have also a positive impact in reducing heart failure (HF). Technological advances have also contributed to improving the quality of care in patients with diabetes. The use of technology, such as continuous glucose monitoring systems (CGM), has improved significantly glucose and glycated haemoglobin A1c (HbA1c) values, while limiting the frequency of hypoglycaemia. Other technological support derives from the use of predictive algorithms that need to be refined to help predict those subjects who are at great risk of developing the disease and/or its complications, or who may require care by other specialists. In this review we also provide recommendations for the optimal use of the new medications; sodium‐glucose co‐transporter‐2 inhibitors (SGLT2i) and Glucagon‐like peptide‐receptor agonists 1 (GLP1RA) in the primary care setting considering the relevance of these drugs for the management of T2DM also in its early stage. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

14. Natriuretic peptides: role in the diagnosis and management of heart failure: a scientific statement from the Heart Failure Association of the European Society of Cardiology, Heart Failure Society of America and Japanese Heart Failure Society

Author

Tsutsui, Hiroyuki, primary, Albert, Nancy M., additional, Coats, Andrew J.S., additional, Anker, Stefan D., additional, Bayes‐Genis, Antoni, additional, Butler, Javed, additional, Chioncel, Ovidiu, additional, Defilippi, Christopher R., additional, Drazner, Mark H., additional, Felker, G. Michael, additional, Filippatos, Gerasimos, additional, Fiuzat, Mona, additional, Ide, Tomomi, additional, Januzzi, James L., additional, Kinugawa, Koichiro, additional, Kuwahara, Koichiro, additional, Matsue, Yuya, additional, Mentz, Robert J., additional, Metra, Marco, additional, Pandey, Ambarish, additional, Rosano, Giuseppe, additional, Saito, Yoshihiko, additional, Sakata, Yasushi, additional, Sato, Naoki, additional, Seferovic, Petar M., additional, Teerlink, John, additional, Yamamoto, Kazuhiro, additional, and Yoshimura, Michihiro, additional

Published
2023
Full Text
View/download PDF

16. Participation in a clinical trial is associated with lower mortality but not lower risk of HF hospitalization in patients with heart failure: observations from the ESC EORP Heart Failure Long-Term Registry

Author

Kapelios, Chris J, primary, Benson, Lina, additional, Crespo-Leiro, Maria G, additional, Anker, Stefan D, additional, Coats, Andrew J S, additional, Chioncel, Ovidiu, additional, Filippatos, Gerasimos, additional, Lainscak, Mitja, additional, McDonagh, Theresa, additional, Mebazaa, Alexandre, additional, Metra, Marco, additional, Piepoli, Massimo F, additional, Rosano, Giuseppe M C, additional, Ruschitzka, Frank, additional, Savarese, Gianluigi, additional, Seferovic, Petar M, additional, Volterrani, Maurizio, additional, Maggioni, Aldo P, additional, and Lund, Lars H, additional

Published
2023
Full Text
View/download PDF

17. PARTICIPATION IN A CLINICAL TRIAL IS ASSOCIATED WITH LOWER MORTALITY IN PATIENTS WITH HEART FAILURE: OBSERVATIONS FROM THE EUROBSERVATIONAL RESEARCH PROGRAMME OF THE EUROPEAN SOCIETY OF CARDIOLOGY HEART FAILURE LONG-TERM REGISTRY

Author

Kapelios, Christos, primary, Benson, Lina, additional, Crespo-Leiro, Maria Generosa, additional, Anker, Stefan D., additional, Coats, Andrew J.S., additional, Filippatos, Gerasimos S., additional, Lainscak, Mitja J., additional, McDonagh, Theresa, additional, Mebazaa, Alexandre, additional, Metra, Marco, additional, Piepoli, Massimo Francesco, additional, rosano, giuseppe, additional, Ruschitzka, Frank Thomas, additional, Savarese, Gianluigi, additional, Seferovic, Petar M., additional, Volterrani, Maurizio, additional, Maggioni, Aldo Pietro, additional, and Lund, Lars, additional

Published
2023
Full Text
View/download PDF

21. Epicardial and Pericardial Biopsy

Author

Maisch, Bernhard, Ristić, Arsen D., Seferović, Petar M., Tsang, Teresa S. M., Maisch, Bernhard, Ristić, Arsen D., Seferović, Petar M., and Tsang, Teresa S. M.

Published
2011
Full Text
View/download PDF

28. Frontiers and Emerging Procedures

Author

Maisch, Bernhard, Ristić, Arsen D., Seferović, Petar M., Tsang, Teresa S. M., Maisch, Bernhard, Ristić, Arsen D., Seferović, Petar M., and Tsang, Teresa S. M.

Published
2011
Full Text
View/download PDF

29. A Historical Perspective

Author

Maisch, Bernhard, Ristić, Arsen D., Seferović, Petar M., Tsang, Teresa S. M., Maisch, Bernhard, Ristić, Arsen D., Seferović, Petar M., and Tsang, Teresa S. M.

Published
2011
Full Text
View/download PDF

34. Targeted therapies in genetic dilated and hypertrophic cardiomyopathies: From molecular mechanisms to therapeutic targets

Author

de Boer, Rudolf A, Heymans, Stephane, Backs, Johannes, Carrier, Lucie, Coats, Andrew J S, Dimmeler, Stefanie, Eschenhagen, Thomas, Filippatos, Gerasimos, Gepstein, Lior, Hulot, Jean-Sebastien, Knöll, Ralph, Kupatt, Christian, Linke, Wolfgang A, Seidman, Christine E, Tocchetti, Carlo Gabriele, van der Velden, Jolanda, Walsh, Roddy, Seferovic, Petar M, Thum, Thomas, de Boer, Rudolf A, Heymans, Stephane, Backs, Johanne, Carrier, Lucie, Coats, Andrew J S, Dimmeler, Stefanie, Eschenhagen, Thoma, Filippatos, Gerasimo, Gepstein, Lior, Hulot, Jean-Sebastien, Knöll, Ralph, Kupatt, Christian, Linke, Wolfgang A, Seidman, Christine E, Tocchetti, Carlo Gabriele, van der Velden, Jolanda, Walsh, Roddy, Seferovic, Petar M, and Thum, Thomas

Abstract

Genetic cardiomyopathies are disorders of the cardiac muscle, most often explained by pathogenic mutations in genes encoding sarcomere, cytoskeleton or ion channel proteins. Clinical phenotypes such as heart failure and arrhythmia are classically treated with generic drugs, but aetiology-specific and targeted treatments are lacking. As a result, cardiomyopathies still present a major burden to society, and affect many young and older patients. The Translational Committee of the Heart Failure Association (HFA) and the Working Group of Myocardial Function of the European Society of Cardiology (ESC) organized a workshop to discuss recent advances in molecular and physiological studies of various forms of cardiomyopathies. The study of cardiomyopathies has intensified after several new study setups became available, such as induced pluripotent stem cells, 3D printing of cells, use of scaffolds and engineered heart tissue, with convincing human validation studies. Furthermore, our knowledge on the consequences of mutated proteins has deepened, with relevance for cellular homeostasis, protein quality control and toxicity, often specific to particular cardiomyopathies, with precise effects explaining the aberrations. This has opened up new avenues to treat cardiomyopathies, using contemporary techniques from the molecular toolbox, such as gene editing and repair using CRISPR-Cas9 techniques, antisense therapies, novel designer drugs, and RNA therapies. In this article, we discuss the connection between biology and diverse clinical presentation, as well as promising new medications and therapeutic avenues, which may be instrumental to come to precision medicine of genetic cardiomyopathies.

Published
2022

35. Patiromer for the management of hyperkalemia in heart failure with reduced ejection fraction: the DIAMOND trial

Author

Butler, Javed, primary, Anker, Stefan D, additional, Lund, Lars H, additional, Coats, Andrew J S, additional, Filippatos, Gerasimos, additional, Siddiqi, Tariq Jamal, additional, Friede, Tim, additional, Fabien, Vincent, additional, Kosiborod, Mikhail, additional, Metra, Marco, additional, Piña, Ileana L, additional, Pinto, Fausto, additional, Rossignol, Patrick, additional, van der Meer, Peter, additional, Bahit, Cecilia, additional, Belohlavek, Jan, additional, Böhm, Michael, additional, Brugts, Jasper J, additional, Cleland, John G F, additional, Ezekowitz, Justin, additional, Bayes-Genis, Antoni, additional, Gotsman, Israel, additional, Goudev, Assen, additional, Khintibidze, Irakli, additional, Lindenfeld, Joann, additional, Mentz, Robert J, additional, Merkely, Bela, additional, Montes, Eliodoro Castro, additional, Mullens, Wilfried, additional, Nicolau, Jose C, additional, Parkhomenko, Aleksandr, additional, Ponikowski, Piotr, additional, Seferovic, Petar M, additional, Senni, Michele, additional, Shlyakhto, Evgeny, additional, Cohen-Solal, Alain, additional, Szecsödy, Peter, additional, Jensen, Klaus, additional, Dorigotti, Fabio, additional, Weir, Matthew R, additional, and Pitt, Bertram, additional

Published
2022
Full Text
View/download PDF

38. Right heart dysfunction and failure in heart failure with preserved ejection fraction: mechanisms and management. Position statement on behalf of the Heart Failure Association of the European Society of Cardiology

Author

Gorter, Thomas M., van Veldhuisen, Dirk J., Bauersachs, Johann, Borlaug, Barry A., Celutkiene, Jelena, Coats, Andrew J.S., Crespo‐Leiro, Marisa G., Guazzi, Marco, Harjola, Veli‐Pekka, Heymans, Stephane, Hill, Loreena, Lainscak, Mitja, Lam, Carolyn S.P., Lund, Lars H., Lyon, Alexander R., Mebazaa, Alexandre, Mueller, Christian, Paulus, Walter J., Pieske, Burkert, Piepoli, Massimo F., Ruschitzka, Frank, Rutten, Frans H., Seferovic, Petar M., Solomon, Scott D., Shah, Sanjiv J., Triposkiadis, Filippos, Wachter, Rolf, Tschöpe, Carsten, and de Boer, Rudolf A.

Published
2018
Full Text
View/download PDF

39. Epidemiology and one‐year outcomes in patients with chronic heart failure and preserved, mid‐range and reduced ejection fraction: an analysis of the ESC Heart Failure Long‐Term Registry

Author

Chioncel, Ovidiu, Lainscak, Mitja, Seferovic, Petar M., Anker, Stefan D., Crespo‐Leiro, Maria G., Harjola, Veli‐Pekka, Parissis, John, Laroche, Cecile, Piepoli, Massimo Francesco, Fonseca, Candida, Mebazaa, Alexandre, Lund, Lars, Ambrosio, Giuseppe A., Coats, Andrew J., Ferrari, Roberto, Ruschitzka, Frank, Maggioni, Aldo P., and Filippatos, Gerasimos

Published
2017
Full Text
View/download PDF

40. ‘heartfailurematters.org’, an educational website for patients and carers from the Heart Failure Association of the European Society of Cardiology: objectives, use and future directions

Author

Wagenaar, Kim P., Rutten, Frans H., Klompstra, Leonie, Bhana, Yusuf, Sieverink, Floor, Ruschitzka, Frank, Seferovic, Petar M., Lainscak, Mitja, Piepoli, Massimo F., Broekhuizen, Berna D.L., Strömberg, Anna, Jaarsma, Tiny, Hoes, Arno W., and Dickstein, Kenneth

Published
2017
Full Text
View/download PDF

45. Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society

Author

Lyon, Alexander R., Dent, Susan, Stanway, Susanna, Earl, Helena, Brezden‐Masley, Christine, Cohen‐Solal, Alain, Tocchetti, Carlo G., Moslehi, Javid, Groarke, John D., Bergler‐Klein, Jutta, Khoo, Vincent, Tan, Li Ling, Anker, Markus S., Haehling, Stephan, Maack, Christoph, Pudil, Radek, Barac, Ana, Thavendirnathan, Paaladinesh, Ky, Bonnie, Neilan, Tomas G., Belenkov, Yury, Rosen, Stuart D., Iakobishvili, Zaza, Sverdlov, Aaron L., Hajjar, Ludhmila A., Macedo, Ariane V. S., Manisty, Charlotte, Ciardiello, Fortunato, Farmakis, Dimitrios, De Boer, Rudolf A., Skouri, Hadi, Suter, Thomas M., Cardinale, Daniela, Witteles, Ronald M., Fradley, Michael G., Herrmann, Joerg, Cornell, Robert F., Wechelaker, Ashutosh, Mauro, Michael J., Milojkovic, Dragana, Lavallade, Hugues, Ruschitzka, Frank, Coats, Andrew J. S., Seferovic, Petar M., Chioncel, Ovidiu, Thum, Thomas, Bauersachs, Johann, Andres, M. Sol, Wright, David J., López‐Fernández, Teresa, Plummer, Chris, Lenihan, Daniel, Imperial College London, Duke University [Durham], The Royal Marsden, University of Cambridge [UK] (CAM), Mount Sinai Hospital [Toronto, Canada] (MSH), Marqueurs cardiovasculaires en situation de stress (MASCOT (UMR_S_942 / U942)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité)-Université Sorbonne Paris Nord, Hôpital Lariboisière-Fernand-Widal [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), University of Naples Federico II = Università degli studi di Napoli Federico II, Vanderbilt University Medical Center [Nashville], Vanderbilt University [Nashville], Brigham & Women’s Hospital [Boston] (BWH), Harvard Medical School [Boston] (HMS), Medizinische Universität Wien = Medical University of Vienna, Monash University [Melbourne], Shanghai Center for Plant Stress Biology [CAS] (PSC), Chinese Academy of Sciences [Beijing] (CAS), German Center for Cardiovascular Research (DZHK), Berlin Institute of Health (BIH), Georg-August-University = Georg-August-Universität Göttingen, Hannover Medical School [Hannover] (MHH), Charles University [Prague] (CU), Georgetown University [Washington] (GU), University Health Network, University of Toronto, University of Pennsylvania, Massachusetts General Hospital [Boston], Sechenov First Moscow State Medical University, University College of London [London] (UCL), Tel Aviv University (TAU), University of Newcastle [Australia] (UoN), Universidade de São Paulo = University of São Paulo (USP), Università degli studi della Campania 'Luigi Vanvitelli' = University of the Study of Campania Luigi Vanvitelli, University of Cyprus [Nicosia] (UCY), University Medical Center Groningen [Groningen] (UMCG), American University of Beirut Faculty of Medicine and Medical Center (AUB), University of Bern, IRCCS Ospedale San Raffaele [Milan, Italy], Stanford University, Mayo Clinic [Rochester], Memorial Sloan Kettering Cancer Center (MSKCC), Hammersmith Hospital NHS Imperial College Healthcare, King's College Hospital (KCH), University hospital of Zurich [Zurich], University of Warwick [Coventry], Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS San Raffaele Pisana), University of Belgrade [Belgrade], Emergency Institute for Cardiovascular Diseases 'Prof. Dr. C.C. Iliescu' [Bucharest, Romania], University of Medicine and Pharmacy 'Carol Davila' Bucharest (UMPCD), Royal Brompton Hospital, Liverpool Heart and Chest Hospital NHS Trust [UK] (LH&CH), La Paz University Hospital, Newcastle Upon Tyne Hospitals NHS Foundation Trust, Washington University School of Medicine in St. Louis, Washington University in Saint Louis (WUSTL), leboeuf, Christophe, Lyon, Alexander R, Dent, Susan, Stanway, Susanna, Earl, Helena, Brezden-Masley, Christine, Cohen-Solal, Alain, Tocchetti, Carlo G, Moslehi, Javid, Groarke, John D, Bergler-Klein, Jutta, Khoo, Vincent, Tan, Li Ling, Anker, Markus S, von Haehling, Stephan, Maack, Christoph, Pudil, Radek, Barac, Ana, Thavendirnathan, Paaladinesh, Ky, Bonnie, Neilan, Tomas G, Belenkov, Yury, Rosen, Stuart D, Iakobishvili, Zaza, Sverdlov, Aaron L, Hajjar, Ludhmila A, Macedo, Ariane V S, Manisty, Charlotte, Ciardiello, Fortunato, Farmakis, Dimitrio, De Boer, Rudolf A, Skouri, Hadi, Suter, Thomas M, Cardinale, Daniela, Witteles, Ronald M, Fradley, Michael G, Herrmann, Joerg, Cornell, Robert F, Wechelaker, Ashutosh, Mauro, Michael J, Milojkovic, Dragana, de Lavallade, Hugue, Ruschitzka, Frank, Coats, Andrew J S, Seferovic, Petar M, Chioncel, Ovidiu, Thum, Thoma, Bauersachs, Johann, Andres, M Sol, Wright, David J, López-Fernández, Teresa, Plummer, Chri, Lenihan, Daniel, Lyon, Alexander R., Brezden‐masley, Christine, Cohen‐solal, Alain, Tocchetti, Carlo G., Groarke, John D., Bergler‐klein, Jutta, Anker, Markus S., Haehling, Stephan, Neilan, Tomas G., Rosen, Stuart D., Sverdlov, Aaron L., Hajjar, Ludhmila A., Macedo, Ariane V. S., De Boer, Rudolf A., Suter, Thomas M., Witteles, Ronald M., Fradley, Michael G., Cornell, Robert F., Mauro, Michael J., Lavallade, Hugue, Coats, Andrew J. S., Seferovic, Petar M., Andres, M. Sol, Wright, David J., and López‐fernández, Teresa

Subjects
Male, Heart failure, Androgen Antagonists, Antineoplastic Agents, Middle Aged, Risk Assessment, Cardiotoxicity, Risk prediction, [SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, Cardio-oncology, risk factor, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, Cardiovascular Diseases, Heart Disease Risk Factors, Risk Factors, Neoplasms, Humans, Female, Aged
Abstract

This position statement from the Heart Failure Association of the European Society of Cardiology Cardio-Oncology Study Group in collaboration with the International Cardio-Oncology Society presents practical, easy-to-use and evidence-based risk stratification tools for oncologists, haemato-oncologists and cardiologists to use in their clinical practice to risk stratify oncology patients prior to receiving cancer therapies known to cause heart failure or other serious cardiovascular toxicities. Baseline risk stratification proformas are presented for oncology patients prior to receiving the following cancer therapies: anthracycline chemotherapy, HER2-targeted therapies such as trastuzumab, vascular endothelial growth factor inhibitors, second and third generation multi-targeted kinase inhibitors for CML targeting BCR-ABL, multiple myeloma therapies (proteasome inhibitors and immunomodulatory drugs), RAF and MEK inhibitors or androgen deprivation therapies. Applying these risk stratification proformas will allow clinicians to stratify cancer patients into low, medium, high and very high risk of cardiovascular complications prior to starting treatment, with the aim of improving personalised approaches to minimise the risk of cardiovascular toxicity from cancer therapies. This article is protected by copyright. All rights reserved.

Published
2020

46. In-hospital and 1-year mortality associated with diabetes in patients with acute heart failure: results from the ESC-HFA Heart Failure Long-Term Registry

Author

Targher, Giovanni, Dauriz, Marco, Laroche, Cécile, Temporelli, Pier Luigi, Hassanein, Mahmoud, Seferovic, Petar M., Drozdz, Jaroslaw, Ferrari, Roberto, Anker, Stephan, Coats, Andrew, Filippatos, Gerasimos, Crespo-Leiro, Maria G., Mebazaa, Alexandre, Piepoli, Massimo F., Maggioni, Aldo Pietro, and Tavazzi, Luigi

Published
2017
Full Text
View/download PDF

47. Feasibility of the cardiac output response to stress test in suspected heart failure patients

Author

Charman, Sarah J, primary, Okwose, Nduka C, additional, Taylor, Clare J, additional, Bailey, Kristian, additional, Fuat, Ahmet, additional, Ristic, Arsen, additional, Mant, Jonathan, additional, Deaton, Christi, additional, Seferovic, Petar M, additional, Coats, Andrew J S, additional, Hobbs, F D Richard, additional, MacGowan, Guy A, additional, and Jakovljevic, Djordje G, additional

Published
2022
Full Text
View/download PDF

48. Targeted therapies in genetic dilated and hypertrophic cardiomyopathies: from molecular mechanisms to therapeutic targets. A position paper from the Heart Failure Association (HFA) and the Working Group on Myocardial Function of the European Society of Cardiology (ESC)

Author

de Boer, Rudolf A., primary, Heymans, Stephane, additional, Backs, Johannes, additional, Carrier, Lucie, additional, Coats, Andrew J.S., additional, Dimmeler, Stefanie, additional, Eschenhagen, Thomas, additional, Filippatos, Gerasimos, additional, Gepstein, Lior, additional, Hulot, Jean‐Sebastien, additional, Knöll, Ralph, additional, Kupatt, Christian, additional, Linke, Wolfgang A., additional, Seidman, Christine E., additional, Tocchetti, C. Gabriele, additional, van der Velden, Jolanda, additional, Walsh, Roddy, additional, Seferovic, Petar M., additional, and Thum, Thomas, additional

Published
2022
Full Text
View/download PDF

49. Preventing heart failure: a position paper of the Heart Failure Association in collaboration with the European Association of Preventive Cardiology

Author

Piepoli, Massimo F., primary, Adamo, Marianna, additional, Barison, Andrea, additional, Bestetti, Reinaldo B., additional, Biegus, Jan, additional, Böhm, Michael, additional, Butler, Javed, additional, Carapetis, Jonathan, additional, Ceconi, Claudio, additional, Chioncel, Ovidiu, additional, Coats, Andrew, additional, Crespo‐Leiro, Maria G., additional, de Simone, Giovanni, additional, Drexel, Heinz, additional, Emdin, Michele, additional, Farmakis, Dimitros, additional, Halle, Martin, additional, Heymans, Stephane, additional, Jaarsma, Tiny, additional, Jankowska, Ewa, additional, Lainscak, Mitja, additional, Lam, Carolyn S.P., additional, Løchen, Maja‐Lisa, additional, Lopatin, Yuri, additional, Maggioni, Aldo, additional, Matrone, Benedetta, additional, Metra, Marco, additional, Noonan, Katharine, additional, Pina, Ileana, additional, Prescott, Eva, additional, Rosano, Giuseppe, additional, Seferovic, Petar M., additional, Sliwa, Karen, additional, Stewart, Simon, additional, Uijl, Alicia, additional, Vaartjes, Ilonca, additional, Vermeulen, Roel, additional, Monique Verschuren, W. M., additional, Volterrani, Maurizio, additional, von Haehling, Stephan, additional, and Hoes, Arno, additional

Published
2022
Full Text
View/download PDF

50. Preventing heart failure: a position paper of the Heart Failure Association in collaboration with the European Association of Preventive Cardiology

Author

Piepoli, Massimo F, primary, Adamo, Marianna, additional, Barison, Andrea, additional, Bestetti, Reinaldo B, additional, Biegus, Jan, additional, Böhm, Michael, additional, Butler, Javed, additional, Carapetis, Jonathan, additional, Ceconi, Claudio, additional, Chioncel, Ovidiu, additional, Coats, Andrew, additional, Crespo-Leiro, Maria G, additional, de Simone, Giovanni, additional, Drexel, Heinz, additional, Emdin, Michele, additional, Farmakis, Dimitros, additional, Halle, Martin, additional, Heymans, Stephane, additional, Jaarsma, Tiny, additional, Jankowska, Ewa, additional, Lainscak, Mitja, additional, Lam, Carolyn S P, additional, Løchen, Maja-Lisa, additional, Lopatin, Yuri, additional, Maggioni, Aldo, additional, Matrone, Benedetta, additional, Metra, Marco, additional, Noonan, Katharine, additional, Pina, Ileana, additional, Prescott, Eva, additional, Rosano, Giuseppe, additional, Seferovic, Petar M, additional, Sliwa, Karen, additional, Stewart, Simon, additional, Uijl, Alicia, additional, Vaartjes, Ilonca, additional, Vermeulen, Roel, additional, Verschuren, W M, additional, Volterrani, Maurizio, additional, Von Haehling, Stephan, additional, and Hoes, Arno, additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results